# US 2020/0390761 A1 · Treating cancer with atr inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390761 A1
- Document ID: US20200390761A1
- Status: Published application
- Kind: A1
- Application number: 17/003,554
- Filed: 2020-08-26
- Published: 2020-12-17
- Earliest claimed: 2011-09-30
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: John Robert POLLARD; Philip Michael REAPER
- Web page: https://patentgrep.com/patent/US20200390761A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

This invention relates to methods and compositions for treating pancreatic cancer. More specifically, this invention relates to treating pancreatic cancer with certain ATR inhibitors in combination with gemcitabine and/or radiation therapy. This invention also relates to methods and compositions for treating non-small cell lung cancer. More specifically, this invention relates to treating non-small cell lung cancer with an ATR inhibitor in combination with cisplatin or carboplatin, etoposide, and ionizing radiation.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method for treatment of pancreatic cancer in a patient, comprising administering to the patient in need thereof an effective amount of a compound of formula 822:
in combination with gemcitabine, radiation, or gemcitabine and radiation.

### Claim 24 (depends on 23)

The method of claim 23, wherein the treatment with the compound is in combination with gemcitabine.

### Claim 25 (depends on 23)

The method of claim 23, wherein the treatment with the compound in in combination with radiation.

### Claim 26 (depends on 23)

The method of claim 23, wherein the treatment with the compound in combination with gemcitabine and radiation.

### Claim 27

A method of killing hypoxic pancreatic cancer cells in a patient, comprising administering to a patient in need thereof an effective amount of a compound of formula 822:
in combination with gemcitabine, radiation, or gemcitabine and radiation.

### Claim 28 (depends on 27)

The method of claim 27, wherein the compound is administered in combination with gemcitabine.

### Claim 29 (depends on 27)

The method of claim 27, wherein the compound is administered in combination with radiation.

### Claim 30 (depends on 27)

The method of claim 27, wherein the compound is administered in combination with gemcitabine and radiation.

### Claim 31 (depends on 27)

The method of claim 27, wherein the hypoxic pancreatic cancer cells display resistance to gemcitabine or radiation.
